疾控中心主任罗谢尔·瓦伦斯基(Rochelle Walensky)在周四晚上给出了最后的签名，为某些人群推荐Moderna和强生疫苗增强剂，为增强剂注射开始进入这些新符合条件的美国人的怀抱开了绿灯。哪个品牌将由个人决定。
“这些建议是我们保护尽可能多的人免遭新冠肺炎侵害的根本承诺的又一个例子。证据表明，美国批准的所有三种新冠肺炎疫苗都是安全的——已经提供的4亿多剂疫苗证明了这一点。而且，它们在降低严重疾病、住院和死亡风险方面都非常有效，即使是在广泛传播的德尔塔变种中，”她在一份声明中说。
疾控中心的独立小组当天早些时候一致投票支持这一决定。
该小组建议，对于65岁及以上的人，以及因潜在健康状况或工作或生活地点而面临更高风险的18岁以下的人，Moderna疫苗接受者在初始疗程后至少六个月注射第三剂。
这与辉瑞疫苗接受者第三次加强剂量的推荐相一致。
建议18岁及以上的人在接种第一剂疫苗至少两个月后接种第二剂强生疫苗。
该小组还为允许混合和匹配加强剂量扫清了道路，这意味着他们将允许人们获得不同的品牌作为加强剂，而不是用于初级疫苗接种。
然而，与美国食品和药物管理局相呼应的是，疾控中心顾问今天并没有说任何增强剂组合比另一种更受欢迎。
疾控中心的咨询投票紧随美国食品和药物管理局周三授权这些增强剂的行动，并与美国食品和药物管理局和疾控中心上个月授权的辉瑞疫苗增强剂保持一致。
CDC signs off on Moderna, J&J boosters, mixing and matching doses
CDC Director Rochelle Walensky gave the final signoff on Thursday evening to recommend both Moderna and Johnson & Johnson vaccine boosters for certain populations, giving the green light for booster shots to start going into the arms of these newly eligible Americans. The decision of which brand will be up to the individual.
"These recommendations are another example of our fundamental commitment to protect as many people as possible from COVID-19. The evidence shows that all three COVID-19 vaccines authorized in the United States are safe – as demonstrated by the over 400 million vaccine doses already given. And, they are all highly effective in reducing the risk of severe disease, hospitalization, and death, even in the midst of the widely circulating Delta variant," she said in a statement.
The CDC's independent panel voted unanimously to support that decision earlier in the day.
The panel recommended a third dose for Moderna vaccine recipients at least six months after a person's initial course for those 65 and older, and those as young as 18 who are at higher risk due to their underlying health conditions, or where they work or live.
This aligns with what was recommended for a third booster dose for recipients of the Pfizer vaccine.
A second dose for those that received a one-shot Johnson & Johnson vaccine was recommended for anyone 18 years and older, at least two months after their first dose.
The panel also cleared the way for allowing mixing and matching of booster doses, meaning they will allow for people to get a different brand as a booster than was used for a primary vaccination.
Echoing the FDA however, CDC advisors today did not say any booster combination was preferred over another.
CDC's advisory vote follows -- and falls in line with -- FDA's move Wednesday to authorize those boosters, and aligns with what FDA and CDC authorized for the Pfizer vaccine booster shots last month.
